Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/folinic acid (FA) in refractory advanced high-grade neuroendocrine cancer (HG-NEC) of gastroenteropancreatic (GEP) or unknown origin.

Document Type

Article

Publication Date

2-4-2020

Publication Title

Journal of clinical oncology

Volume

38(4 Suppl)

Share

COinS